Treatment of the Patient with Refractory Headache

Chronic Daily Headache (SJ Wang, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Chronic Daily Headache

Abstract

Purpose of Review

To review recent studies outlining the management of refractory primary headache patients, including emerging therapies such as neuromodulation. This includes both noninvasive and invasive neuromodulation techniques. Recent studies on the management of medication overuse headache were also reviewed.

Recent Findings

There is no consensus as yet on the definitions of refractory chronic migraine and chronic cluster headache although there is broad agreement on some aspects of these terms. The importance of identifying medication overuse headache and dealing effectively with it has been highlighted in several studies although there is still not consensus on how best to achieve the cessation of medication overuse. Some recommend the use of preventative medication together with medication cessation, while others do not. Recent studies on neuromodulation have used both noninvasive vagal nerve stimulation as well invasive techniques. Recent studies using noninvasive vagal nerve stimulation for chronic migraine have been disappointing although the data in chronic cluster headache are more encouraging. Similarly, recent studies on occipital nerve stimulation have again been more positive in chronic cluster headache and generally negative in chronic migraine.

Summary

In recent years, new forms of neuromodulation have emerged and long-term follow-up data from previous invasive neuromodulation techniques have become available. The sphenopalatine ganglion has been increasingly targeted by various interventions in several different headache types. Sphenopalatine ganglion stimulation is yielding encouraging data for the treatment of chronic cluster headache. New studies and long-term follow-up data from previous studies have provided further evidence for the benefit of deep brain stimulation for refractory chronic cluster headache although the exact target location is still debated. Data from phase 3 trials using CGRP monoclonal antibodies in chronic migraine and chronic cluster headache, if positive, may herald a long overdue, new and effective treatment for our refractory headache patients.

Keywords

Chronic migraine Chronic cluster headache Refractory headache Medication overuse headache Neuromodulation 

Notes

Compliance with Ethical Standards

Conflict of Interest

Alessandro S. Zagami declares honoraria from Novartis and Teva and serves as an Associate Editor for Cephalalgia.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014;5(2):87–99.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006;26(9):1168–70.CrossRefPubMedGoogle Scholar
  3. 3.
    Martelletti P, Katsarava Z, Lampl C, Magis D, Bendtsen L, Negro A, et al. Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain. 2014;15:47.Google Scholar
  4. 4.
    Mitsikostas DD, Edvinsson L, Jensen RH, Katsarava Z, Lampl C, Negro A, et al. Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation. J Headache Pain. 2014;15:79.Google Scholar
  5. 5.
    Levin M. Refractory headache: classification and nomenclature. Headache. 2008;48(6):783–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Schulman EA, Peterlin BL, Lake AE 3rd, Lipton RB, Hanlon A, Siegel S, et al. Defining refractory migraine: results of the RHSIS Survey of American Headache Society members. Headache. 2009;49(4):509–18.CrossRefPubMedGoogle Scholar
  7. 7.
    D'Amico D, Leone M, Grazzi L, Bussone G. When should “chronic migraine” patients be considered “refractory” to pharmacological prophylaxis? Neurol Sci. 2008;29(Suppl 1):S55–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Schulman EA, Lake AE 3rd, Goadsby PJ, Peterlin BL, Siegel SE, Markley HG, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008;48(6):778–82.Google Scholar
  9. 9.
    Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.[Erratum appears in Cephalalgia. 2007 Aug;27(8):962]. Cephalalgia. 2007;27(7):814–23.CrossRefPubMedGoogle Scholar
  10. 10.
    Diener HC, Dodick DW, Goadsby PJ, Bigal ME, Bussone G, Silberstein SD, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009;29(10):1021–7.Google Scholar
  11. 11.
    Silberstein SC, Lipton RD, Dodick DW. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;72(2):170–80.CrossRefGoogle Scholar
  12. 12.
    Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.Google Scholar
  13. 13.
    Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.Google Scholar
  14. 14.
    Sun-Edelstein C, Rapoport AM. Update on the pharmacological treatment of chronic migraine. Curr Pain Headache Rep. 2016;20(1):6.CrossRefPubMedGoogle Scholar
  15. 15.
    Calandre EP, Garcia-Leiva JM, Rico-Villademoros F, Vilchez JS, Rodriguez-Lopez CM. Pregabalin in the treatment of chronic migraine: an open-label study. Clin Neuropharmacol. 2010;33(1):35–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Bigal M, Rapoport A, Sheftell F, Tepper D, Tepper S. Memantine in the preventive treatment of refractory migraine. Headache. 2008;48(9):1337–42.CrossRefPubMedGoogle Scholar
  17. 17.
    Pascual-Gomez J, Gracia-Naya M, Leira R, Mateos V, Alvaro-Gonzalez LC, Hernando I, et al. [Zonisamide in the preventive treatment of refractory migraine]. Zonisamida en el tratamiento preventivo de la migrana refractaria 2010;50(3):129–32.Google Scholar
  18. 18.
    Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Selective ML. Serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Cochrane Database Syst Rev. 2015;4:CD002919.PubMedGoogle Scholar
  19. 19.
    Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):9–160.Google Scholar
  20. 20.
    Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629-808.Google Scholar
  21. 21.
    Messlinger K, Jensen RH. Editorial. Cephalalgia. 2017;37(4):303–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609.Google Scholar
  23. 23.
    Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L. Complete detoxification is the most effective treatment of medication-overuse headache: a randomized controlled open-label trial. Cephalalgia. 2017;  https://doi.org/10.1177/0333102417737779.
  24. 24.
    Bendtsen L, Munksgaard S, Tassorelli C, Nappi G, Katsarava Z, Lainez M, et al. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia. 2014;34(6):426–33.Google Scholar
  25. 25.
    •• Chiang C-C, Schwedt TJ, Wang S-J, Dodick DW. Treatment of medication-overuse headache: a systematic review. Cephalalgia. 2016;36(4):371–86. An extensive review of all the current available data on the management of medication overuse headache. CrossRefPubMedGoogle Scholar
  26. 26.
    Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827–32.CrossRefPubMedGoogle Scholar
  27. 27.
    Eller M, Gelfand AA, Riggins NY, Shiboski S, Schankin C, Goadsby PJ. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. Neurology. 2016;86(9):856–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Robbins NM, Ito H, Scheinman MM, Goadsby PJ. Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. Neurology. 2016;87(24):2522–6.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Chou DE, Tso AR, Goadsby PJ. Aprepitant for the management of nausea with inpatient IV dihydroergotamine. Neurology. 2016;87(15):1613–6.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Tso AR, Patniyot IR, Gelfand AA, Goadsby PJ. Increased rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment. Neurology. 2017;89(3):279–83.CrossRefPubMedGoogle Scholar
  31. 31.
    Lauritsen C, Mazuera S, Lipton RB, Ashina S. Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. J Headache Pain. 2016;17(1):106.Google Scholar
  32. 32.
    Pomeroy JL, Marmura MJ, Nahas SJ, Viscusi ER. Ketamine infusions for treatment refractory headache. Headache. 2017;57(2):276–82.CrossRefPubMedGoogle Scholar
  33. 33.
    Ford RG, Ford KT. Continuous intravenous dihydroergotamine in the treatment of intractable headache. Headache. 1997;37(3):129–36.CrossRefPubMedGoogle Scholar
  34. 34.
    Fontaine D, Lazorthes Y, Mertens P, Blond S, Geraud G, Fabre N, et al. Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension. J Headache Pain. 2010;11(1):23–31.CrossRefPubMedGoogle Scholar
  35. 35.
    Ambrosini A, Schoenen J. Commentary on Fontaine et al.: “Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension”. J Headache Pain. 2010;11(1):21–2.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Leone M, Franzini A, Proietti Cecchini A, Bussone G. Success, failure, and putative mechanisms in hypothalamic stimulation for drug-resistant chronic cluster headache. Pain. 2013;154(1):89–94.CrossRefPubMedGoogle Scholar
  37. 37.
    Akram H, Miller S, Lagrata S, Hyam J, Jahanshahi M, Hariz M, et al. Ventral tegmental area deep brain stimulation for refractory chronic cluster headache. Neurology. 2016;86(18):1676–82.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Zhu S, McGeeney. When indomethacin fails: additional treatment options for “indomethacin responsive headaches”. Curr Pain Headache Rep. 2015;19:7.CrossRefPubMedGoogle Scholar
  39. 39.
    Rozen TD. How effective is melatonin as a preventive treatment for hemicrania continua? A clinic-based study. Headache. 2015;55(3):430–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Spears R. Is gabapentin an effective treatment choice for hemicrania continua? J Headache Pain. 2006;10(4):271–5.Google Scholar
  41. 41.
    Miller S, Correia F, Lagrata S, Matharu MS. OnabotulinumtoxinA for hemicrania continua: open label experience in 9 patients. J Headache Pain. 2015;16:19.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Schoenen J, Jensen RH, Lanteri-Minet M, Lainez MJ, Gaul C, Goodman AM, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia. 2013;33(10):816–30.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Tso AR, Marin J, Goadsby P. Noninvasive vagus nerve stimulation for treatment of indomethacin-sensitive headaches. JAMA Neurol. 2017;74(10):1266–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Trimboli M, Al-Kaisy A, Andreou AP, Murphy M, Lambru G. Non-invasive vagus nerve stimulation for the management of refractory primary chronic headaches: a real-world experience. Cephalalgia. 2017;  https://doi.org/10.1177/0333102417731349.
  45. 45.
    Androulakis XM, Krebs KA, Ashkenazi A. Hemicrania continua may respond to repetitive sphenopalatine ganglion block: a case report. Headache. 2016;56(3):573–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Dodick DW, Silberstein SD, Reed KL, Deer TR, Slavin KV, Huh B, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2015;35(4):344–58.Google Scholar
  47. 47.
    Rozen TD. Triggering events and new daily persistent headache: age and gender differences and insights on pathogenesis-a clinic based study. Headache. 2016;56(1):164–73.CrossRefPubMedGoogle Scholar
  48. 48.
    Goadsby PJ, Boes C. New daily persistent headache. J Neurol Neurosurg Psychiatry. 2002;72(Suppl 2):6–9.Google Scholar
  49. 49.
    Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: the EVENT study. Neurology. 2016;87(5):529–38.Google Scholar
  50. 50.
    Gaul C, Diener H-C, Silver N, Magis D, Reuter U, Andersson A, et al. Non-invasive vagus nerve stimulation for PREVention and acute treatment of chronic cluster headache (PREVA): a randomised controlled study. Cephalalgia. 2016;36(6):534–46.Google Scholar
  51. 51.
    Morris J, Straube A, Diener H-C, Ahmed F, Silver N, Walker S, et al. Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache. J Headache Pain. 2016;17:43.Google Scholar
  52. 52.
    Gaul C, Magis D, Liebler E, Straube A. Effects of non-invasive vagus nerve stimulation on attack frequency over time and expanded response rates in patients with chronic cluster headache: a post hoc analysis of the randomised, controlled PREVA study. J Headache Pain. 2017;18(1):22.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, et al. Non-invasive vagus nerve stimulation for the acute treatment of cluster headache: findings from the randomized, double-blind, sham-controlled ACT1 study. Headache. 2016;56(8):1317–32.Google Scholar
  54. 54.
    Schwedt TJ, Green AL, Dodick DW. Occipital nerve stimulation for migraine: update from recent multicenter trials. Prog Neurol Surg. 2015;29:117–26.CrossRefPubMedGoogle Scholar
  55. 55.
    Mueller O, Diener HC, Dammann P, Rabe K, Hagel V, Sure U, et al. Occipital nerve stimulation for intractable chronic cluster headache or migraine: a critical analysis of direct treatment costs and complications. Cephalalgia. 2013;33(16):1283–91.Google Scholar
  56. 56.
    Kinfe TM, Pintea B, Roeske S, Guresir A, Guresir E, Vatter H. Percutaneous nerve field stimulation (PENS) of the occipital region as a possible predictor for occipital nerve stimulation (ONS) responsiveness in refractory headache disorders? A feasibility study. Cephalalgia. 2016;36(8):779–89.CrossRefPubMedGoogle Scholar
  57. 57.
    Miller S, Watkins L, Matharu M. Predictors of response to occipital nerve stimulation in refractory chronic migraine. Cephalalgia. 2017;  https://doi.org/10.1177/0333102417728747.
  58. 58.
    Magis D, Gerard P, Schoenen J. Invasive occipital nerve stimulation for refractory chronic cluster headache: what evolution at long-term? Strengths and weaknesses of the method. J Headache Pain. 2016;17:8.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Wilbrink LA, Teernstra OP, Haan J, van Zwet EW, Evers SM, Spincemaille GH, et al. Occipital nerve stimulation in medically intractable, chronic cluster headache. The ICON study: rationale and protocol of a randomised trial. Cephalalgia. 2013;33(15):1238–47.CrossRefPubMedGoogle Scholar
  60. 60.
    De Agostino R, Federspiel B, Cesnulis E, Sandor PS. High-cervical spinal cord stimulation for medically intractable chronic migraine. Neuromodulation. 2015;18(4):289–96. discussion 96.CrossRefPubMedGoogle Scholar
  61. 61.
    Arcioni R, Palmisani S, Mercieri M, Vano V, Tigano S, Smith T, et al. Cervical 10 kHz spinal cord stimulation in the management of chronic, medically refractory migraine: a prospective, open-label, exploratory study. Eur J Pain. 2016;20(1):70–8.Google Scholar
  62. 62.
    Puledda F, Goadsby PJ. Current approaches to neuromodulation in primary headaches: focus on vagal nerve and sphenopalatine ganglion stimulation. Curr Pain Headache Rep. 2016;20(7):47.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Robbins MS, Robertson CE, Kaplan E, Ailani J, Charleston IV L, et al. The sphenopalatine ganglion: anatomy, pathophysiology, and therapeutic targeting in headache. Headache. 2016;56(2):240–58.Google Scholar
  64. 64.
    Bratbak DF, Nordgard S, Stovner LJ, Linde M, Folvik M, Bugten V, et al. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headache. Cephalalgia. 2016;36(6):503–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Bratbak DF, Nordgard S, Stovner LJ, Linde M, Dodick DW, Aschehoug I, et al. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine. Cephalalgia. 2017;37(4):356–64.CrossRefPubMedGoogle Scholar
  66. 66.
    Fang L, Jingjing L, Ying S, Lan M, Tao W, Nan J. Computerized tomography-guided sphenopalatine ganglion pulsed radiofrequency treatment in 16 patients with refractory cluster headaches: twelve- to 30-month follow-up evaluations. Cephalalgia. 2016;36(2):106–12.CrossRefPubMedGoogle Scholar
  67. 67.
    Loomba V, Upadhyay A, Kaveeshvar H. Radiofrequency ablation of the sphenopalatine ganglion using cone beam computed tomography for intractable cluster headache. Pain Physician. 2016;19(7):E1093–6.PubMedGoogle Scholar
  68. 68.
    Jurgens TP, Schoenen J, Rostgaard J, Hillerup S, Lainez MJ, Assaf AT, et al. Stimulation of the sphenopalatine ganglion in intractable cluster headache: expert consensus on patient selection and standards of care. Cephalalgia. 2014;34(13):1100–10.CrossRefPubMedGoogle Scholar
  69. 69.
    Meng DW, Zhang JG, Zheng Z, Wang X, Luo F, Chronic Bilateral ZK. Sphenopalatine ganglion stimulation for intractable bilateral chronic cluster headache: a case report. Pain Physician. 2016;19(4):E637–42.PubMedGoogle Scholar
  70. 70.
    • Barloese MC, Jurgens TP, May A, Lainez JM, Schoenen J, Gaul C, et al. Cluster headache attack remission with sphenopalatine ganglion stimulation: experiences in chronic cluster headache patients through 24 months. J Headache Pain. 2016;17(1):67. Interesting paper providing evidence that sphenopalatine ganglion stimulation can not only be used to abort cluster headache attacks but also prevent them in chronic cluster headache patients. CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Bendersky DC, Hem SM, Yampolsky CG. Unsuccessful pulsed radiofrequency of the sphenopalatine ganglion in patients with chronic cluster headache and subsequent successful thermocoagulation. Pain Practice. 2015;15(5):E40–5.CrossRefPubMedGoogle Scholar
  72. 72.
    •• Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015;80(2):193–9. A comprehensive review of CGRP pharmacology as it relates to migraine. CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Tso AR, Goadsby PJ. Anti-CGRP monoclonal antibodies: the next era of migraine prevention. Curr Treat Options Neurol. 2017;19:27.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1091–100.CrossRefPubMedGoogle Scholar
  75. 75.
    Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, et al. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology. 2016;87(1):41–8.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–34.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute of Neurological Sciences, Prince of Wales Hospital, Level 2, High Street, Randwick, Sydney 2031, Australia and Prince of Wales Hospital Clinical SchoolUniversity of New South WalesSydneyAustralia

Personalised recommendations